The merger effectively hands control to Slate with FULC shareholders retaining only a residual 5% stake plus a special dividend. The low ownership level combined with early-stage pipeline risk (SLTE-1009 still pre-Phase 1) suggests limited upside for current FULC holders. Monitor the shareholder vote and HSR clearance timeline - any deal disruption risk could further pressure FULC shares.
Price Chart
Executive Summary
Fulcrum Therapeutics (FULC) filed a Rule 425 transcript of a joint conference call with Slate Medicines, confirming the all-stock merger announced August 16, 2026. The call reiterates the deal structure: Fulcrum stockholders will own ~5% of the combined company, Slate stockholders ~55.9%, PIPE investors ~39.1%, with a special cash dividend of excess cash above $20.3M to pre-merger Fulcrum holders. The deal transforms FULC into a migraine-focused biotech under Slate management (ticker expected to become SLTE), funded by a $245M PIPE providing cash runway into 2029.
Key Financial Metrics
Key Facts
- Pre-merger Fulcrum stockholders to own ~5% of the combined company on a fully-diluted basis (down from 100% control).
- Pre-merger Slate stockholders to own ~55.9%, PIPE investors ~39.1%.
- Fulcrum to contribute net cash of $20.3M at close, with excess cash (~$270M) paid as a special dividend to pre-merger Fulcrum holders.
- $245M concurrent private placement led by Frazier Life Sciences with participation from Forbion, RA Capital, Deep Track, Foresite, OrbiMed, RTW, Mingxin.
- Combined company expected to be renamed Slate Medicines, Inc. and trade as SLTE on Nasdaq.
- Slate lead candidate SLTE-1009 (anti-PACAP/VIP mAb) Phase 1 data expected mid-2027, Phase 2 in H2 2027.
- Second program SLTE-2100 (bispecific PACAP/VIP+CGRP) expected to enter clinic H2 2027.
- Cash runway expected into 2029; deal expected to close Q4 2026 subject to stockholder approval and HSR clearance.
Financial Impact
Fulcrum shareholders are diluted from 100% to ~5% ownership; ~$270M excess cash returned as special dividend. No standalone revenue or EPS for the combined entity provided in this filing.
Risk Factors
- Shareholder vote required - large institutional holders may oppose the 5% residual stake.
- HSR antitrust clearance required.
- Clinical risk: SLTE-1009 and SLTE-2100 are early-stage (preclinical/Phase 1) with no human efficacy data.
- Combined company has no approved products; reliance on $245M PIPE for runway into 2029.
- Ticker change to SLTE may trigger index/ETF selling of FULC positions.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 425 Filing (Primary) | 0001193125-26-353282 |
| Document: 0001193125-26-353282-index-headers.html | 0001193125-26-353282 |
| Document: 0001193125-26-353282-index.html | 0001193125-26-353282 |
| Document: 0001193125-26-353282.txt | 0001193125-26-353282 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 2, 2026 4w ago | S-4 | $3.85 $3.70 | ▲ +3.90% | ▲ +3.57% | $3.67 (+4.55%) |
Aug 17, 2026 6w ago | 425 | $3.84 $3.78 | ▲ +1.56% | ▼ −0.42% | $3.67 (+4.30%) |
Aug 17, 2026 6w ago | 425 | $3.84 $3.78 | ▼ −1.56% | ▲ +0.42% | $3.67 (−4.30%) |
Aug 17, 2026 6w ago | 8-K | $3.84 $3.78 | ▼ −1.56% | ▲ +0.42% | $3.67 (−4.30%) |
Aug 17, 2026 6w ago | Press Release | $3.84 $3.78 | ▼ −1.56% | ▲ +0.42% | $3.67 (−4.30%) |
Aug 10, 2026 7w ago | 8-K | $3.75 $3.82 | ▲ +1.87% | ▲ +2.78% | $3.67 (−2.00%) |
Jul 15, 2026 11w ago | 3 | $3.50 $3.71 | ▲ +6.00% | ▲ +2.38% | $3.67 (+5.00%) |
Jun 11, 2026 16w ago | Institutional Cluster | $3.55 $3.59 | ▲ +1.13% | ▼ −0.76% | $3.67 (+3.52%) |
Apr 27, 2026 22w ago | 8-K | $7.72 $6.76 | ▼ −12.44% | ▼ −17.39% | $3.67 (−52.40%) |
Apr 27, 2026 22w ago | Press Release | $7.72 $6.76 | ▼ −12.44% | ▼ −17.39% | $3.67 (−52.40%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access